Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU in 2022

Genito Urinary System and Sex Hormones

Uncomplicated UTI Treatment: Challenges and Opp...

Urinary tract infection (UTI), also known as acute cystitis, is an infection in any part of the urinary system, including the kidneys, bladder, ureters, and urethra. It is one of the most common in...

Jan 23, 2023

MedTech News for QuantuMDx, Medtronic, Exactech, and ProciseDx
QuantuMDx & Menarini’s Agreement; TruClear System Launched by Medtronic in India; FDA 510(k) Clearance for TriVerse Primary Knee Replacement System; FDA Clearance to ProciseDx’s Reactive Protein (CRP) Assay and ProciseDx Instrument; Evolution Optiks’s Enrollment of LFR-260 Phoropter in US; Kardium First-in-Human Clinical Study of the New Globe Pulsed Field System

QuantuMDx and Menarini Announced an Agreement for the Distribution of the Q-POCTM Platform On November 2, 2022, QuantuMDx Group Limited, a UK-based developer of transformational Point-of-Need molecular diagnostics, and A.Menarini Diagnostics S.r.I. (Menarini), announced an exclusive distribution agreement for Qu...

Find More
Pharma News for Amgen, AstraZeneca, Sanofi, Anavex, Sensorion, GSK
Amgen’s Olpasiran Candidate; GSK’s Novel Antibiotic for Urinary Tract Infections; AstraZeneca and Sanofi’s Beyfortus Approval; FDA Orphan Designation to Anavex’s Anavex2-73; FDA Rare Pediatric Disease Designation to Sensorion’s OTOF-GT; GSK’s Blenrep Fails in Phase III Trial in R/R Multiple Myeloma

Amgen Reports Promising Mid-stage Results for its Olpasiran Candidate  Amgen has reported encouraging mid-stage results for its olpasiran candidate for lowering lipoprotein(a) - a risk factor for atherosclerotic cardiovascular disease - and now plans to move forward with a phase III program as soon as possi...

Find More
MedTech Updates for Neuspera, Abbott, and ZEISS,
Neuspera Medical’s Nuvella System; Abbott Presented the Data for FreeStyle Libre 2 System; ZEISS Receives FDA 510(k) Clearance for MTLawton; FDA 510(k) Clearance for the GHOST 3D-Printed Titanium Spacer System; Thermo Fisher Scientific Launched CE-IVD Marked TaqPath Enteric Bacterial Select Panel; BIOCORP and Merck Announced New Partnership

Neuspera Medical Announces First Successful Implant of the Nuvella™ System in the Second Phase of Its Sans-Uui Ide Clinical Trial On October 10, 2022, Neuspera Medical, a medical device company involved in the development of implantable devices for patients suffering from chronic illnesses, announced that...

Find More

More Views & Analysis

focal-segmental-glomerulosclerosis-market-outlook
Focal Segmental Glomerulosclerosis Market: Unfolding Insights into the Future

Currently, there are no FDA-approved therapies for FSGS. However, the therapeutic focal segmental glomerulosclerosis market in the seven major geographies mainly comprises off-label focal segmental glomerulosclerosis treatment options. The off-label therapies majorly include nonimmune therapies in conjunction wi...

Find More

Pharma News for Amgen BioNTech and Gilead
Amgen Announced the Result of its CodeBreak-200 Trial; FDA Clears Bristol-Myers Squibb’s Deucravacitinib; BioNTech’s Amplified CAR-T Therapy; TIL Therapy Improves on Yervoy in Melanoma; GSK’s Daprodustat will have to face FDA Advisory Committee; Breakthrough Therapy Status to Pfizer’s Group B Strep Vaccine; EU Approves Gilead’ Tecartus; Gilead’ Trodelvy Results in TROPiCs-02 Trial

Amgen Reveals the Top-line Result of its CodeBreak-200 trial of Lumakras in Lung Cancer The top-line result of Amgen's CodeBreak-200 trial of Lumakras in lung cancer was presented in abstract form at ESMO two weeks ago, showing a 34% improvement in progression-free survival (PFS) compared to chemotherapy. The fu...

Find More

adpkd-treatment-outlook
Advancing Therapeutic Outlook for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Treatment

Key Highlights The US approval of Jynarque added the much-needed push to the ADPKD treatment market.In the coming years, Bardoxolone methyl is expected to be an effective therapy for ADPKD treatment.The current ADPKD treatment only aims to delay the disease progression rather than completely cure the disease, wh...

Find More

Genital Warts
VP-102: A Potential Emerging Drug for Genital Warts

Warts are small, benign fleshy growths of the skin or mucous membranes caused by various strains of the human papillomavirus (HPV). Genital Warts (condyloma acuminatum) are the clinical manifestations of a sexually transmitted infection caused by HPV. HPV is the most common sexually transmitted infection ...

Find More

Biogen terminates ALS Pact with Karyopharm; AbbVie’s Immunological Drug Skyrizi; NICE Backs Astellas’ Oral Therapy Evrenzo; Roche’s Crenezumab Fails in Clinical Trial; FDA Grants Fast Track Designation to Dianhydrogalactitol; Sierra Oncology Submits NDA for Momelotinib

Biogen terminates USD 217 Million ALS Pact with Karyopharm Biogen has backed out of the four-year-old partnership with Karyopharm on a drug candidate for the neurological disease amyotrophic lateral sclerosis, which could have cost the US biotech up to USD 217 million. The 2018 agreement that granted Biogen righ...

Find More

Top Drugs Losing Patent Protection in 2022
Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU in 2022

Patent protection and expiration is one of the hot topics in the healthcare industry. Patent protection results in high sales and profits for the initial developers and innovators of the drugs, and as per various estimates, the gross profit margins for the Patent protected drugs exceed 90% in some cases. However, t...

Find More

Myocardial Infarction
Myocardial Infarction...

Myocardial infarction (MI), colloquially known as “heart attack” is caused by decreased or compl.....

Find More
Acute Ischemic Stroke (AIS)
Acute Ischemic Stroke (AI...

Acute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, whic.....

Find More
Rheumatoid Arthritis
Rheumatoid Arthritis...

Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....

Find More